Literature DB >> 1894943

Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin.

G J Weil1, P J Lammie, F O Richards, M L Eberhard.   

Abstract

This study assessed changes in circulating parasite antigen levels after diethylcarbamazine (DEC) and ivermectin treatment of bancroftian filariasis to determine effects of these drugs on adult Wuchereria bancrofti in vivo. Thirty adult Haitians with microfilaremia were treated with 1 mg of ivermectin to reduce counts of microfilariae. Later, subjects were treated with either one or two 200 micrograms/kg doses of ivermectin or with 12 daily 6 mg/kg doses of DEC. Macrofilaricidal activity of these drugs was indirectly monitored by measuring circulating W. bancrofti antigen by EIA. Antigen levels fell by 75% after DEC and by 34% after ivermectin. These results suggest that low-dose ivermectin treatment followed by a standard course of DEC is a more effective macrofilaricidal regimen for W. bancrofti than either of the multidose ivermectin regimens used in this study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894943     DOI: 10.1093/infdis/164.4.814

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  The resurgence of lymphatic filariasis in the Nile delta.

Authors:  M Harb; R Faris; A M Gad; O N Hafez; R Ramzy; A A Buck
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

2.  Epidemiological screening of lymphatic filariasis among immigrants using dipstick colloidal dye immunoassay.

Authors:  A Wan Omar; O Sulaiman; S Yusof; G Ismail; M S Fatmah; N Rahmah; A A Khairul
Journal:  Malays J Med Sci       Date:  2001-07

3.  Impact of microfilaremia on maintenance of a hyporesponsive cellular immune response in Brugia-infected gerbils (Meriones unguiculatus).

Authors:  S C Bosshardt; S U Coleman; C S McVay; K L Jones; T R Klei
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

4.  Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.

Authors:  Frank O Richards; Abel Eigege; Emmanuel S Miri; Alphonsus Kal; John Umaru; Davou Pam; Lindsay J Rakers; Yohanna Sambo; Jacob Danboyi; Bako Ibrahim; Solomon E Adelamo; Gladys Ogah; Danjuma Goshit; O Kehinde Oyenekan; Els Mathieu; P Craig Withers; Yisa A Saka; Jonathan Jiya; Donald R Hopkins
Journal:  PLoS Negl Trop Dis       Date:  2011-10-11

5.  Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis.

Authors:  Britt J Andersen; Jessica Kumar; Kurt Curtis; Nelly Sanuku; Samson Satofan; Christopher L King; Peter U Fischer; Gary J Weil
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

6.  Translating Research into Reality: Elimination of Lymphatic Filariasis from Haiti.

Authors:  Patrick J Lammie; Mark L Eberhard; David G Addiss; Kimberly Y Won; Madsen Beau de Rochars; Abdel N Direny; Marie Denise Milord; Jack Guy Lafontant; Thomas G Streit
Journal:  Am J Trop Med Hyg       Date:  2017-10       Impact factor: 2.345

Review 7.  Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.

Authors:  Philip J Budge; Carly Herbert; Britt J Andersen; Gary J Weil
Journal:  PLoS Negl Trop Dis       Date:  2018-05-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.